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ABSTRACT
Objective: Prostate cancer is the second most common cancer in men. One of the efforts in the treatment of prostate cancer is by inhibiting histone 
lysine demethylase. Derivative compounds of coumarine, N-oxalylglycine, organoselenium, organosulfur, and pyridine have been reported to be active 
against two types of histone lysine demethylase (KDM) enzymes, KDM4E and KDM5B. This study aims to study the interactions of these derivatives 
with KDM.
Methods: In this study, we performed computational studies, including molecular docking and molecular dynamics (MDs) simulations, and toxicity 
prediction, to assess the compounds’ activities toward three other KDM enzymes, KDM1A, KDM4A, and KDM4C.
Results: Molecular docking simulations showed that a derivative compound of N-oxalylglycine, (R)-3-(4-[benzyloxy]phenyl)-2-(carboxyformamido)
propanoic acid, and a derivative compound of pyridine, 3-(4-methoxybenzylamino)pyridine-2,4-dicarboxylic acid, has the highest affinity toward 
KDM. These results were confirmed in MDs studies which showed strong interactions at the active site of the five receptors. Toxicity prediction results 
show that the derivative compounds of coumarine, N-oxalylglycine, organoselenium, organosulfur, and pyridine are classified in category (high class), 
which suggests that the safety is not guaranteed, but is likely, not carcinogenic and nongenotoxic.
Conclusion: Several coumarin, N-oxalylglycine, organoselenium, organosulfur, and pyridine derivative compounds are predicted to be able to interact 
strongly with KDM. The results in this study are useful for further studies in the development of novel anticancer drugs that target KDM.
Keywords: Histone lysine demethylase, Coumarine, N-oxalylglycine, Organoselenium, Organosulfur, Pyridine, Molecular docking, Molecular dynamics, 
Toxicity prediction.
INTRODUCTION
Prostate cancer is a leading cause of deaths worldwide with around 
307,000 recorded deaths in 2012. It is also the second most common 
type of cancer in men and the fifth highest cause of death by cancer 
in men, with 6.6% mortality rate. Around 1.1 million people were 
diagnosed with cancer in 2012, which was around 15% of all cancers 
diagnosed in men. In Indonesia, prostate cancer is the third most 
common type of cancer in men, following lung and colorectal cancer [1].
Existing therapies for prostate cancer include removal of the tumor, 
radiotherapy, and chemotherapy. For prostate cancer, androgen 
deprivation therapy is the most commonly used therapy in which 
androgen activity in the body is reduced through surgical or medical 
castration, both of which were found to be equally effective [2]. 
However, there are many risks associated with cancer therapy using 
current technology, especially with the use of anticancer drugs. For 
instance, a study found that patients undergoing cancer chemotherapy 
were more likely to experience adverse drug reactions, including 
anemia, leucopenia, and fever [3]. Therefore, novel anticancer drugs 
that have low toxicities and minimal side effects are needed.
One possible target for novel anticancer agents is the histone lysine 
demethylase (KDM) enzyme, which is an epigenetic regulatory enzyme 
that maintains chromatin structures. Several data have shown that KDM 
is highly expressed in different types of cancer, including colorectal and 
prostate cancer [4-6]. Studies have also suggested that inhibiting KDM 
activity may lead to cancer cell death due to its role as a regulator for 
cancer potential [7]. Another study suggests that blocking the activity 
of KDM is a potential epigenetic mechanism for suppressing the growth 
of cancer cells, especially in prostate cancer [8].
Various compounds have been shown to have inhibitory activities 
toward KDM, but it is desirable to develop inhibitors derived from 
natural sources, as they typically present low levels of toxicity and is 
an abundant resource. Several studies have shown that substances 
derived from plant sources, including from Phyllanthus emblica and 
Caesalpinia decapetala, exhibit inhibitory activity against HL60 cancer 
cell line [9]. Other studies have shown that coumarin, N-oxalylglycine, 
organoselenium, organosulfur, and pyridine derivatives possess 
inhibitory activities toward two members of the KDM enzyme family, 
KDM5B [10], and KDM4E [11].
In the development of novel drugs, computer simulations play an 
essential role in reducing the time and costs of the development 
process. Molecular docking simulations can be used to quickly screen a 
database of chemical compounds for potential drug molecules. Indeed, 
many studies have been performed in which molecular docking was 
used to discover potential anticancer agents, including the screening 
of potent (peroxisome proliferator-activated receptor-gamma) 
agonists from natural resources [12], the screening of potential BRCA1 
inhibitors [13], docking studies on the interactions of eriodictyol with 
apoptotic proteins [14], and the development of gallic acid structural 
analogs as BCL-XL inhibitors [15].
In this study, we perform computational simulations to study the 
interactions of compounds derived from coumarin, N-oxalylglycine, 
organoselenium, organosulfur, and pyridine with KDM enzymes 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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through molecular docking, molecular dynamics (MDs), and toxicity 
predictions studies. The results of this study will be very beneficial in the 
development of candidate anticancer compounds from natural sources.
METHODS
Macromolecule preparation
Crystal structures of five KDM enzymes were obtained from the protein 
data bank with PDB IDs 4UV8 (KDM1A), 3PDQ (KDM4A), 5FJK (KDM4C), 
2W2I (KDM4E), and 5A3P (KDM5B). For each macromolecule, the 
small molecules (ligands) and water molecules were removed, and 
polar hydrogens and kollman charges were added.
Ligand preparation
The structures of 12 pyridine, five N-oxalylglycine, one coumarin, one 
organoselenium, and one organosulfur derivative compounds were 
built using the ChemOffice suite of programs (Table 1). Geometry 
optimization and density functional theory (DFT) calculations were 
performed in Gaussian using the Becke three-parameter Lee-Yang-Parr 
functional at the 3-21G level.
Molecular docking
Each ligand molecule was prepared for docking using AutoDock Tools 
1.5.6. Hydrogen atoms were added, and partial charges of each atom 
resulted from the DFT calculations were incorporated. Grid maps were 
created by centering the grid box at the position of the natural ligand 
of each macromolecule with a spacing of 0.375 Å and size covering the 
binding cavity of each target. Lamarckian genetic algorithm and 50 
docking runs were used for each simulation.
MDs simulations
Five ligands with the best docking score for each target were chosen 
for further MDs study. MD simulations were carried out using the 
Gromacs 5.1.1 suite of programs. The Amber99sb-ildn force field and 
the general amber force field were used to parameterize the atoms of 
the macromolecules and ligands, respectively. Energy minimization was 
carried out on the macromolecules in vacuum using the steepest descent 
algorithm. Then, the macromolecules were solvated with transferable 
intermolecular potential with 3 points water molecules in an 
octahedron box. Positive and negative ions were added to the system at 
a concentration of 0.15 N to neutralize all charges. Energy minimization 
was again performed on the macromolecule/solvent/ion system to 
release strains resulted from the solvation procedure; the steepest 
descent algorithm was used again. Next, the system was carefully 
heated to 310 K and pressurized to 1 atm using the constant-volume, 
constant-temperature (NVT) and constant-pressure, and constant-
temperature (NPT) ensembles. The Berendsen thermostat coupling 
was used to maintain the system temperature and pressure [16]. The 
particle mesh ewald method [17] with a cutoff value of 5.0 Å was 
used to compute long-range interactions. The stability of the system 
was evaluated by analyzing the root mean square deviation (RMSD) 
and root mean square fluctuation (RMSF) of the protein backbones. 
A production simulation run was carried out on each macromolecule 
for 2 ns. Analysis of the stability of ligand-protein interactions was 
performed by calculating the RMSD and RMSF values of the atoms at 
the protein binding sites throughout the simulation.
Toxicity prediction
Toxicity prediction was performed using Toxtree 2.6.6. Three methods 




Twenty pyridine, N-oxalylglycine, coumarin, organoselenium, and 
organosulfur derivative compounds were docked onto each of the 
five macromolecular targets (KDM1A, KDM4A, KDM4C, KDM4E, and 
KDM5B). Five of the best ligands with the lowest binding energy from 
each target were selected for further study (Table 2). The results show 
that out of the 20 ligands, only nine ligands were part of the five ligands 
with the highest affinity to the targets. All of the ligands binding to 
KDM1A, KDM4E, and KDM5B have lower binding energies compared to 
their respective reference ligands, showing a promising sign that these 
ligands have good affinities toward their targets. Ligand eight binds 
the active site of KDM1A with a binding free energy of 2.06 kcal/mol 
lower than that of the reference ligand. Meanwhile, the ligands with the 
highest affinity toward KDM4E and KDM5B only resulted in binding 
free energies of 1.77 kcal/mol (ligand 14) and 0.78 kcal/mol (ligand 11) 
lower than the reference ligands, respectively. However, all of the 
five ligands chosen for KDM4A, and some of the ligands for KDM4C, 
showed lower affinities than their reference ligands. This may suggest 
poor performance as potential inhibitors of the targets, but further 
interaction studies may reveal otherwise.
Interactions between the small molecular ligands and the active sites 
of the macromolecular targets comprise mainly of hydrogen bonds, 
with the ligands mainly acting as hydrogen bond donors and the 
protein residues as hydrogen bond acceptors. Most of the hydrogen 
bonds formed were fairly strong, with average bond lengths of about 
2.7 Å.
Table 1: The 20 ligands used in this study
S.No. Test compounds
1 1H-pyrrole-2,3-dicarboxylic acid







8 (R)-3-(4-(benzyloxy) phenyl)-2-(carboxyformamido) 
propanoic acid
9 2-phenylbenzo[d][1,2]selenazol-3 (2H)-one
10 2-p-tolylbenzo[d] isothiazol-3 (2H)-one
11 (R)-2-(carboxyformamido)-3-(4-(2-(3-methoxyphenyl) 
allyloxy) phenyl) propanoic acid
12 (R)-3-(4-(3-fluorobenzyloxy) phenyl)-2-(carboxyformamido) 
propanoic acid
13 6,7-dihydroxy-2H-chromen-2-one
14 3-(o-toluidine) pyridine-2,4-dicarboxylic acid
15 (R)-2-(carboxyformamido)-3-(4-(2-(4-(pyrrolidin-1-yl) 
phenyl) allyloxy) phenyl) propanoic acid
16 3-(4-methoxybenzylamino) pyridine-2,4-dicarboxylic acid
17 3-(4-fluorophenylamino) pyridine-2,4-dicarboxylic acid
18 3-(4-pyridinyl)-2-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl] 
acrylonitrile
19 3-(2-aminophenylamino) pyridine-2,4-dicarboxylic acid
20 (Z)-2-(1-methyl-1H-benzo[d] imidazol-2-yl)-3-(pyridin-4-yl) 
acrylonitrile
Table 2: Binding free energies of the ligands to five different 
KDM (kcal/mol)
Ligand KDM1A KDM4A KDM4C KDM4E KDM5B
Reference ligand −6.66 −8.55 −7.26 −5.58 −5.37
2 −6.75
6 −6.28 −6.61
8 −8.72 −7.49 −7.37 −6.97 −5.90
11 −8.21 −7.10 −6.15
12 −8.15 −6.88 −7.20 −5.89
14 −7.35
15 −8.44 −7.06 −5.60
16 −7.17 −6.45 −6.61 −6.36 −6.11
18 −5.98
Only the top five ligands with the highest affinity toward each target were 
chosen
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Interaction dynamics
Further studies were conducted on the five ligands with the lowest 
binding free energy from each macromolecular target. The interaction 
dynamics between these ligands and their targets were studied using 
MDs simulations with explicit solvent. The purpose of such simulations 
was to examine the effects of ligand binding on the residues of the 
protein targets, especially at the binding regions. Strong binders tend to 
lower the movements of the atoms they bind to, and generally stabilize 
the binding region of the protein. This was analyzed by calculating the 
RMSD of the protein binding site atoms throughout the 2 ns simulation. 
In addition, the overall fluctuation of each atom in the binding site was 
also analyzed by calculating the RMSF.
The RMSD values of the KDM1A protein backbone were compared to 
those of the KDM1A in complex with ligand 8, 11, 12, 15, and 16 (Fig. 1). 
It can be observed that most of the ligands were able to stabilize the 
protein in general, marked by lower RMSD values compared to the 
lone protein. However, the RMSD values of the ligand 16-protein 
complex did not differ from those of the lone protein, signifying that 
this ligand did not stabilize the protein. Most enzyme inhibitors work 
by binding strongly to the active sites of the enzymes and competing 
with their natural substrates, and also stabilizing the enzyme structure 
and prevents conformation changes that are required for the enzyme 
to catalyze reactions. Hence, by reducing the atomic deviations of the 
protein target, ligands 8, 11, 12, and 15 have shown the potential to 
act as KDM1A inhibitors. This is also supported by examining the RMSF 
values of the binding site atoms of the enzyme (Fig. 2). Ligands 8, 11, 
and 15 binds strongly with the residues at the active site of the enzyme, 
as seen by the low RMSF values of these atoms compared with the 
values of the lone enzyme. However, ligand 11 was able to lower the 
RMSF values of the active site atoms significantly compared to the other 
ligands. These low-fluctuation atoms belong to the residues responsible 
for binding with the ligand, namely, Gly285, Ser286, Gly287, Val288, 
Ser289, Glu308, Ala309, Arg310, Gly314, Gly315, Arg316, Val317, 
Gly330, Ala331, Thr624, Leu625, Pro626, Trp751, Trp756, Ala757, 
Ser760, Tyr761, Gly800, Glu801, Ala809, Thr810, Val811, and Ala814.
The same analysis was performed on the other four targets: KDM4A, 
KDM4C, KDM4E, and KDM5B. In the simulations of KDM4A and its enzyme-
ligand complexes, ligands 8 and 16 resulted in lower backbone RMSD 
values than those of the sole enzyme, with ligand 16 providing the lowest 
RMSD (Fig. 3). Interestingly, ligands 12 and 11 provided higher RMSD 
values, which may suggest that these ligands do not interact well with the 
target, resulting in volatile movements of the protein backbone. However, 
it seems that all of the ligands interacted well with the active site of the 
enzyme, as seen by the relatively low change in RMSF values compared to 
the sole enzyme, with ligand 6 resulting in the lowest RMSF values.
As for KDM4C, the same ligand resulted in very low backbone deviation 
and binding site atom fluctuation throughout the simulation, namely, 
ligand 6, making it a strong candidate for a KDM4C inhibitor (Fig. 4).
An interesting phenomenon was observed in the simulations involving 
KDM4E; none of the ligands succeeded in stabilizing the enzyme. 
Although ligand 14 resulted in similar RMSD values to the lone enzyme, 
it did not manage to lower the RMSF values of the binding site atoms. As 
for the other ligands, the RMSD values of the protein backbone greatly 
increased, suggesting very poor interaction with the target.
Another interesting phenomenon was observed in the simulations with 
KDM5B. Ligand 8 poorly interacted with the binding site of the enzyme, 
resulting in significantly higher RMSD and RMSF values compared to 
the lone enzyme (Fig. 5). Ligands 11, 15, and, to a lesser extent, 12, 
showed strong interactions with the enzyme active site.
Toxicity prediction
Predicted toxicity properties of the 20 ligands were obtained using the 
Toxtree software based on Cramer rules, Kroes TTC decision tree, and 
the Benigni-Bossa rulebase.
Fig. 1: Backbone root mean square deviation variation of the 
histone lysine demethylase 1A (KDM1A) sole protein (black), and 
in complex with ligand 8 (green), 15 (red), 11 (yellow), 12 (blue), 
and 16 (purple)
Fig. 2: Root mean square deviation of atoms in the active site 
of KDM1A: Lone protein (black), and in complex with ligand 8 
(green), 15 (red), 11 (yellow), 12 (blue), and 16 (purple)
Fig. 3: Backbone root mean square deviation variation of the 
histone lysine demethylase 4A (KDM4A) sole protein (black), and 
in complex with ligand 6 (green), 16 (red), 12 (yellow), 11 (blue), 
and 8 (purple)
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Based on the Cramer rules, the ligands were classified as Class III high 
toxicity, which means that at high concentrations, these compounds 
pose a risk of producing toxic effects. This is due to the functional 
groups of the ligands which are similar to many known toxins, such as 
cyclic, heterocyclic, and heteroaromatic functional groups.
The Kroes TTC decision tree concluded that the 20 ligands are predicted 
to have carcinogenic properties at doses of more than 0.15 µg/day. 
However, there is an 86-97% probability of risk reduction if a dose of 
<0.15 µg/day is used.
Finally, based on the Benigni-Bossa rulebase, some of the ligands are 
predicted to have genotoxic, carcinogenic properties due to having 
ligands such as hydrazine.
Although the toxicity predictions conclude that many of the ligands 
may have toxic or carcinogenic properties, these are based on statistical 
analysis and laboratory toxicity tests must be carried out to ensure 
their safety.
CONCLUSIONS
Several derivative compounds of pyridine, N-oxalylglycine, 
coumarin, organoselenium, and organosulfur are able to bind 
strongly to lysine-specific histone demethylase. The compounds 
(R)-2-(carboxyformamido)-3-(4-(2-(3-methoxyphenyl)allyloxy)phenyl)
propanoic acid (ligand 11), 3-(4-methoxybenzylamino) pyridine-
2,4-dicarboxylic acid (ligand 16), (R)-2-(carboxyformamido)-3-
(4-(furan-2-carbonyloxy) phenyl) propanoic acid (ligand 6), and (R)-
2-(carboxyformamido)-3-(4-(2-(4-(pyrrolidin-1-yl)phenyl)allyloxy)
phenyl) propanoic acid (ligand 15) were able to form very stable 
interactions with the active site of KDM1A, KDM4A, KDM4C, and 
KDM5B, respectively. The results suggest that these compounds have the 
potential to be developed further as KDM inhibitors in cancer therapy.
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